# Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01294787** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 85 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** indacaterol and glycopyrronium bromide (QVA149)
- **DRUG:** placebo
- **DRUG:** tiotropium

## Key facts

- **NCT ID:** NCT01294787
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2013-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294787, "Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01294787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*